Fulcrum Therapeutics (FULC) Revenue (2020 - 2024)
Fulcrum Therapeutics (FULC) posted quarterly Revenue of $80.0 million for Q2 2024, up 8990.91% year-over-year from $880000.0 in Q3 2023, and up 9084.85% quarter-over-quarter from $871000.0 in Q4 2023.
Fulcrum Therapeutics (FULC) Revenue (2020 - 2024) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Revenue for 5 consecutive years, with $80.0 million the latest figure, recorded in Q2 2024.
- In Q2 2024, Revenue rose 8990.91% year-over-year to $80.0 million; the TTM figure through Jun 2025 stood at $80.0 million (down 2.0% YoY), while the FY2024 annual figure was $80.0 million, up 2752.05% from the prior year.
- Revenue climbed to $80.0 million in Q2 2024 per FULC's latest filing, from $871000.0 in the prior quarter.
- Across five years, Revenue topped out at $80.0 million in Q2 2024 and bottomed at $295000.0 in Q1 2023.
- Historically, Revenue has averaged $6.9 million across 5 years, with a median of $1.9 million in 2022.
- Annual changes were most pronounced in 2023 — Revenue sank 88.62% — and 2024, when it soared 8990.91%.
- Fulcrum Therapeutics' Revenue stood at $4.2 million in 2020, then rose by 19.72% to $5.1 million in 2021, then plunged by 86.46% to $685000.0 in 2022, then increased by 27.15% to $871000.0 in 2023, then jumped by 9084.85% to $80.0 million in 2024.
- Business Quant data shows FULC's Revenue at $80.0 million in Q2 2024, $871000.0 in Q4 2023, and $759000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 80.00 Mn |
| Dec 31, 2023 | 871,000.00 |
| Sep 30, 2023 | 759,000.00 |
| Jun 30, 2023 | 880,000.00 |
| Mar 31, 2023 | 295,000.00 |
| Dec 31, 2022 | 685,000.00 |
| Sep 30, 2022 | 1.18 Mn |
| Jun 30, 2022 | 1.88 Mn |
| Mar 31, 2022 | 2.59 Mn |
| Dec 31, 2021 | 5.06 Mn |
| Sep 30, 2021 | 4.94 Mn |
| Jun 30, 2021 | 4.38 Mn |
| Mar 31, 2021 | 4.79 Mn |
| Dec 31, 2020 | 4.23 Mn |
| Sep 30, 2020 | 1.85 Mn |
| Jun 30, 2020 | 2.00 Mn |
| Mar 31, 2020 | 750,000.00 |